4.6 Article

Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States

Journal

AMERICAN JOURNAL OF TRANSPLANTATION
Volume 20, Issue 11, Pages 3225-3233

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1111/ajt.16079

Keywords

antibody biology; clinical research; practice; infection and infectious agents - viral; infectious disease

Funding

  1. National Institutes of Health [R01-HL105704]
  2. National Heart, Blood, and Lung Institute
  3. Charles and Helen Schwab Foundation
  4. Abbott Laboratories

Ask authors/readers for more resources

The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among 10 SOT patients, including the clinical presentation, treatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipient, 1 heart transplant recipient, and 1 lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all 7 hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available